Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879422 | PMC |
| http://dx.doi.org/10.1093/nsr/nwaf004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced mitochondrial biogenesis facilitates the development of cutaneous squamous cell carcinoma.
Cancer Lett
March 2025
Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, China; School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China; Interdisciplinary Research Center of Frontier science and technology, Xi'an Jiaotong University, Xi'an, China. Electronic address:
Mitochondrial malfunction is traditionally viewed as a major factor in tumor growth and malignancy, while recent studies have introduced conflicting views suggesting the necessity of functional mitochondria for tumor growth. Despite these differing perspectives, the specific role of mitochondria in cutaneous squamous cell carcinoma (cSCC) remains poorly understood. In this study, we observed increased mitochondrial abundance and function during the development of cSCC.
View Article and Find Full Text PDFPrion protein fragment (106-126) activates NLRP3 inflammasome and promotes platelet-monocyte/neutrophil interactions, potentially contributing to an inflammatory state.
Front Cell Dev Biol
February 2025
Centre for Advanced Research on Platelet Signaling and Thrombosis Biology, Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Introduction: Prion diseases are neurodegenerative disorders where infectious prion proteins (PrP) featuring an amyloidogenic amino acid sequence, PrP (106-126), accumulate in the brain leading to neuroinflammation while it can also access circulation by breaching the blood-brain barrier. Platelets are highly sensitive cells in blood, which have been widely employed as "peripheral" model for neurons. In addition to their stellar roles in hemostasis and thrombosis, platelets are also known to function as immune cells and possess necessary components of functional inflammasome.
View Article and Find Full Text PDFExploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond.
Pathol Res Pract
March 2025
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address:
Immunotherapy emerges as a promising approach, marked by recent substantial progress in elucidating how the host immune response impacts tumor development and its sensitivity to various treatments. Immune checkpoint inhibitors have revolutionized cancer therapy by unleashing the power of the immune system to recognize and eradicate tumor cells. Among these, inhibitors targeting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have garnered significant attention due to their remarkable clinical efficacy across various malignancies.
View Article and Find Full Text PDFImmune checkpoint inhibitors and myocardial infarction.
J Thromb Thrombolysis
March 2025
Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy since their first approval in 2011. By unleashing the adaptive immune system, non-cardiac and cardiac immune-related adverse events (irAEs) are common and often pose a challenge to multidisciplinary teams treating cancer patients. A significant body of literature reports accelerated atherosclerosis - a key precursor of acute vascular events (AVEs) - with currently approved ICIs (CTLA-4, PD-1, LAG-3, and PD-L1 inhibitors), and some preclinical research also suggests increased thrombogenicity.
View Article and Find Full Text PDFUnleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles.
Bioeng Transl Med
March 2025
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering College of Life Science & Technology, Xinjiang University Urumqi China.
Messenger RNA (mRNA) has emerged as a promising therapeutic strategy for various diseases, including cancer, infectious diseases, and genetic disorders. The mRNA-based therapeutics have gained significant attention due to their ability to regulate targeted cells, activate immune cells, and avoid potential risks associated with DNA-based technology. However, the clinical application of mRNA in cancer therapy is hindered by the instability of RNA, physiological barriers, and the risk of immunogenic hurdles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!